- Trial phase
- Phase 1b
- Time to market
- At least 3-5 years away from potential approval, assuming successful completion of Phase 1b dose expansion, a registrational Phase 2/3 trial, and FDA review. No registrational trial has been initiated yet.
- Why 4/10
- IMA402 is a Phase 1b asset with no upcoming PDUFA or pivotal readout scheduled in the next ~12 months. The most recent catalyst (ESMO 2026 data) has already passed. The next major company catalyst is the SUPRAME Phase 3 readout for anzu-cel (a different asset) in H1 2027. IMA402 is one of several pipeline programs and not the lead asset, so its impact on the stock is moderate.
The next catalyst for IMA402 is continued data maturation from the ongoing Phase 1b dose expansion cohorts, but no specific readout date has been announced. The company's next major binary event is the SUPRAME Phase 3 topline data for anzu-cel (a different asset) expected in H1 2027. IMA402 data will likely be updated at major medical conferences in 2027.
Price Chart
Executive Summary
IMA402 is a Phase 1b TCR bispecific immunotherapy targeting PRAME, a protein found in over 50 cancer types, developed by Immatics N.V. (NASDAQ: IMTX). Updated data presented at the October 2026 ESMO meeting showed a 32% confirmed objective response rate and 91% 1-year overall survival in advanced melanoma patients with high PRAME expression, along with a favorable safety profile. The drug is still early-stage (Phase 1b dose expansion), with no registrational trial design announced or specific upcoming binary catalyst. Immatics has a strong cash position ($772M as of Q2 2026) and a broad PRAME franchise, but IMA402 is one of several pipeline assets behind the lead program anzu-cel (Phase 3). The stock trades near its 52-week low at $6.69 with analyst consensus Strong Buy and a mean price target of $16.40.
How It Works
IMA402 is a TCR (T cell receptor) bispecific drug, a type of immunotherapy designed to bridge a patient's own T cells (immune cells) to cancer cells that display a protein called PRAME on their surface. PRAME is found in many solid tumor types including melanoma, ovarian, lung and others. By binding both the T cell and the cancer cell simultaneously, IMA402 redirects the immune system to attack and kill PRAME-positive tumor cells. It is engineered with a half-life extension to stay in the body longer between doses.
Trial Status
IMA402 is in an ongoing Phase 1b dose expansion study (NCT05958121) evaluating two dose levels as monotherapy and in combination with immune checkpoint inhibitors, focusing on melanoma and gynecologic cancers. Updated data as of June 1, 2026 cutoff (126 patients treated) was presented at ESMO October 2026. Phase 1a dose escalation previously established a favorable safety profile and clinical proof-of-concept.
The Two-Sided Case
Upcoming Catalysts
- Continued data maturation from Phase 1b dose expansion cohorts (no specific date announced)
- Potential data presentations at major 2027 medical conferences (ASCO, ESMO)
- Possible announcement of registrational trial design for IMA402
Source Filing
The SecBot filing or press-release report that triggered this drug report:
https://immatics.com/ PRESS-RELEASE IMTX ·Originating report